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Abstract 
Melanocyte stimulating hormone (MSH) plays an important role in determining the 
cutaneous response to ultraviolet radiation and may also influence melanoma 
progression. We have previously shown that variants of the melanocortin receptor 
present on melanocytes, MC1R, are associated with sun sensitivity and red hair in a UK 
population and therefore now consider the gene as a candidate for melanoma 
susceptibility. We have compared the frequency of known MC1R variants in the second 
and seventh transmembrane domains in 43 melanoma cases and 44 controls. MC1R 
variants were more common in cases than controls (chi 2 = 6.75, 1 d.f.; P = 0.0094) with 
a relative risk to carriers of variant alleles compared with normal homozygotes of 3.91 
(95% c.l.: 1.48-10.35), and a population risk attributable to carriers of 34.6% (95% c.i. 
10.7-52.1%). The Asp84Glu variant was only present in melanoma cases and appears to 
be of particular significance. The contribution of variant MC1R alleles was largely 
independent of skin type. Variants of the MC1R gene are likely to be causally associated 
with the development of melanoma. 
 
 
 
 
 
 
 
Introduction 
The incidence of melanoma is increasing in most Caucasian populations (1–3). The high 
case fatality, coupled with the ubiquity of the main environmental cause, ultraviolet 
radiation, has led to interest in identifying high risk groups and research into the 
underlying biological basis of susceptibility. There appears to be a significant genetic 
contribution to melanoma susceptibility (4), however, the attributable risk of certain 
genetic syndromes such as xeroderma pigmentosum and kindreds harbouring germline 
mutations of p16 may be small (5,6). On the other hand, pigmentation and the 
cutaneous response to ultraviolet irradiation, which also appear to be largely under 
genetic control, are major risk factors for melanoma (1,3). Melanoma rates are an order 
of magnitude higher in whites (Caucasians) than in blacks (Negroes), and even within 
many Caucasian populations a collection of pigmentary characteristics including 
propensity to freckling, pale skin, light or red hair, a tendency to burn and an inability to 
tan are associated with increased risk of melanoma (1,3,7). 
The genetics of human pigmentation appears complex, but analogies can be drawn from 
other mammalian systems. In the mouse the product of the extension locus [the 
melanocyte stimulating hormone receptor, the melanocortin 1 receptor (Mc1r)] 
controls the switch from phaeomelanin (yellow) to eumelanin (black) (8,9). Mice 
homozygous for a loss-of-function mutation in the receptor produce only yellow 
pigment in the hair; (these mice do not spontaneously develop skin tumours, and to 
date no ultraviolet irradiation studies on mice with known Mc1r variants have been 
reported). Mutations in the same gene in cattle and horses results in red and chestnut 
animals respectively (10–12). We have recently shown that, in man, variants of the 
melanocyte stimulating 
hormone are associated with red hair and the propensity to burn rather than tan 
following sun exposure (13). Melanocyte stimulating hormone (αMSH) is a tridecapep-
tide cleaved from its precursor proopiomelanocortin which also gives rise to other 
peptide hormones with pigmentary activity including ACTH (14). αMSH is secreted by 
the anterior pituitary but is also produced peripherally in skin (15) and some, if not all, 
of its effects on melanocytes are mediated through binding to the MC1R, a member of 
the family of G protein coupled transmembrane receptors, and subsequent activation of 
adenyl cyclase (8,16,17). 
There are at least two reasons for anticipating that allelic variants of the MC1R gene 
may be causally associated with melanoma susceptibility. First, given the associations 
between skin type and melanoma, and between MC1R variants and skin type, one might 
expect an over-representation of variant alleles in melanoma subjects. Importantly, 
although the association between skin type and melanoma is marked in some 
populations such as Australia (1,3), in UK studies and in others from Northern Europe 
the relative risk is more modest (18–20); this has been attributed to the low ambient 
ultraviolet irradiation and the high proportion of sensitive skin types in the general 
population (19), but may also reflect the methodological difficulties of classifying 
subjects by skin type (21). It is possible, therefore, that (genotypic) examination for the 
presence of variant alleles may be more revealing than examination of phenotype. A 
second unrelated, but no less cogent, reason for suspecting that MC1R may be a 
candidate susceptibility gene for melanoma, is that as well as playing an important 
physiological role in controlling the switch from phaeomelanin to eumelanin, αMSH 
with or without other growth factors including basic fibroblast growth factor may play 
an important role in stimulating melanoma cell growth and tumour progression (22,23). 
Therefore, we have examined a group of patients with melanoma and a control 
population for MC1R allelic variants. 
 
Results 
We studied the MC1R gene of 43 unrelated patients with cutaneous melanoma and of 44 
unrelated control patients. The skin type of each individual was assessed using a 
modified Fitzpatrick scale (24), and a history of freckling and hair colour taken. We 
found, as expected, a weak association between melanoma and skin type: if skin type 
was treated as a quantitative variable (25), the means of skin type for melanoma 
patients and controls were 2.03 and 2.33 respectively. This difference was just 
statistically significant at the 5% level for a one-tailed test in the predicted direction, i.e., 
lower skin type in the melanoma group (t = 1.70, 81 d.f.; P = 0.046). 
We amplified the MC1R gene by PCR and examined for the presence of previously 
reported variants by sequencing or restriction enzyme digest. Twenty out of 43 
melanoma patients, but only eight out of 44 controls were carriers of variant alleles 
(Table 1). The association of any variant allele with melanoma was statistically 
significant (χ2 = 6.75, 1 d.f.; P = 0.0094). The estimated risk of melanoma for those with 
one or two variant alleles relative to normal homozygotes was 3.91 (95% c.i.: 1.48–
10.35). The population risk attributable to carriers was 34.6% (95% c.i.: 10.7–52.1); 
(this is an estimate of the amount by which the incidence of the disease would be 
reduced if the risk in carriers were reduced to the same level as that in non-carriers; it is 
a somewhat artificial concept but provides some measure of the population impact of 
the carrier status on disease incidence) (26). Of particular note was that the association 
between variant alleles and melanoma was largely accounted for by the Asp84Glu 
variant (aspartate replaced by glutamate at codon 84) which was identified in 10 
melanoma cases, with two of these individuals being homozygous for this change, 
whereas no control case showed this alteration. Clinically, the two subjects homozygous 
for the Asp84Glu variant did not differ from the other melanoma patients, in that these 
individuals developed their melanoma at 42 and 81 years old respectively, whereas the 
overall group developed melanomas at ages ranging from 28 to 86 years, neither patient 
developed more than one melanoma, and hair colour/skin type/freckling 
characteristics were red/skin type I–II/freckles and dark brown/skin type II/freckles 
respectively for the two homozygotes. Interestingly, 24 of the 43 melanoma subjects 
had been previously investigated for p16INK4 mutations (27); only one case contained 
a p16INK4 mutation which had occurred as a somatic event in an individual 
heterozygous for the Asp84Glu variant. 
Three melanoma cases showed the Asp294His variant (aspartate replaced by histidine 
at codon 294), and one additional case showed an Asn91Asp (asparagine replaced by 
aspartate at codon 91) alteration; neither of these changes were seen in the control 
population. By contrast the Val92Met variant (valine to methionine at codon 92) was 
found at similar frequency in both melanoma and control groups. No case in which the 
melanoma and normal skin was sequenced demonstrated a MC1R variant in the 
melanoma alone, consistent with the variants being present in the germline rather than 
resulting from a somatic event; [in addition, a previous allelotype study on cutaneous 
melanoma (including 36 of the 43 melanomas in the present study) detected no allelic 
imbalance on chromosome arm 16q where the humanMC1R gene is located] (32). The 
association between melanoma and carriers of variant MC1R alleles appeared largely 
independent of skin type when examined using the Mantel-Haenszel test (25) (χ2 = 
4.59, 1 d.f.; P = 0.032; the four cases where skin type was not available were excluded). 
Within skin type categories the relative risk for carriers of variant alleles versus normal 
homozygotes was 3.57 (95% c.i.:1.25–10.14). 
 
Discussion 
We show that certain variants of the MC1R are more common in individuals with 
melanoma than in control subjects and that this association is greater than the 
association between melanoma and skin type. Interestingly, one particular allele, the 
Asp84Glu variant which was present in 23% of the melanoma subjects but none of the 
controls (in the present study) accounts for most of this difference. Consideration of 
whether the association between variant alleles and melanoma is acting independently 
of skin type is of biological and clinical relevance. First, in a previous study relating 
MC1R variants to skin type and pigmentary characteristics in a selected British 
population (13), we found the Asp84 Glu change in only two out of 135 subjects 
(including 47 subjects with red/auburn hair and 77 who were skin type I or II). This 
variant is therefore not common even in those thought to be at increased risk of 
melanoma on the basis of pigmentary characteristics or history of sun sensitivity. The 
finding of two individuals homozygous for Asp84Glu in the melanoma group, a genotype 
not previously reported, emphasises the potential importance of this change. On the 
other hand, although the statistical analysis suggests that the effect of genotype appears 
largely independent of skin type, there are a number of legitimate criticisms of the way 
skin type was recorded in the present study. The Fitzpatrick classification, whilst widely 
used and superior to other measures such as measurement of erythema following 
experimental exposure to ultraviolet radiation, is known to be a crude measure of the 
cutaneous response to ultraviolet radiation (24), and telephone enquiry may be less 
sensitive than direct interview. (Self-reported hair colour, except for the extremes of 
hair colour is likely to be prone to considerable error which was why hair colour was 
not formally analysed in the present study.) Nevertheless if the association of MC1R 
alleles and melanoma were acting through skin type, on the basis of previous work (13), 
one would have expected an association to be seen with all the variant alleles. This was 
not the case, and in particular the Val92Met variant was seen at similar frequency in 
both controls and melanoma cases: an alternative explanation is that the Val92Met is a 
neutral polymorphism rather than being associated with skin type. 
The molecular mechanism behind the reported association is not known. In comparison 
with other mammals, the genetics of the MC1R in man has several enigmatic features 
including the nature of the mode of inheritance (28), and at present the functional 
significance of the variants in terms of signal transduction is unclear. Although the 
conservative change from aspartate to glutamate appears minor, aspartate at codon 84 
is highly conserved throughout not only the melanocortin receptor family but also other 
G protein coupled receptors (16,17,29–31). Whilst it is possible that the change we have 
observed may not be the direct cause, but rather may be in linkage disequilibrium with 
some other change outside the coding region of the MC1R gene, the high degree of 
conservation makes a direct causal role for this particular variant plausible. To resolve 
this, studies of the functional significance of the various alleles, and case control studies 
of melanoma in different populations are required. Furthermore, there seem at least 
two possible pathways in which the MC1R may be influencing melanoma development: 
through controlling the switch from phaeomelanin to eumelanin and hence determining 
the ability to protect against ultraviolet radiation; or alternatively, via the effects of MSH 
on melanocyte growth. Studies on non-melanoma skin cancer might prove informative 
in this regard. If no association of the Asp84Glu variant is seen with squamous 
malignancy then it is likely that the association is melanoma specific, a feature favouring 
an influence of MSH on melanocyte growth rather than on the development of 
pigmentary protection. 
 
Materials and Methods 
Patients and controls 
Genomic DNA was isolated as previously described (13,32) from either paraffin-
embedded melanoma, normal skin, or from venous blood of 43 unrelated Caucasian 
patients with a cutaneous melanoma originally excised between 1987 and 1995, and 
from venous blood of 44 unrelated control Caucasian patients with psoriasis. Patients 
with psoriasis recruited from a population survey were used as controls because of 
sample availability, and because there is no evidence of an altered risk of melanoma in 
this population group, nor is there any known association between psoriasis and skin 
type, the use of other (non-melanoma) dermatology outpatients as controls was felt 
inappropriate because of potential bias towards patients with non-melanoma skin 
cancer or patients referred because of concern about skin cancer. The melanoma 
individuals were ascertained through the Departments of Dermatology and Pathology at 
the Royal Victoria Infirmary, Newcastle and Dryburn Hospital, Durham. Control subjects 
were originally ascertained through the response to a request for patients with 
psoriasis in a local televised program on research into psoriasis. All melanoma and 
control individuals (except one melanoma patient who was living in Southern Scotland) 
resided in the North East of England. Forty two of the 43 melanoma patients did not 
have a family history of melanoma (the one case with a family history of melanoma had 
an affected mother only, but did not fulfil the criteria for the diagnosis of atypical mole 
syndrome). Only one patient developed a second cutaneous melanoma, and two 
patients had clinical features consistent with atypical mole syndrome. The age range of 
the melanoma and control groups was 28–86 (median 57.5) and 12–72 (median 49) 
years respectively. Skin type was assessed using a modified Fitzpatrick scale (24) [types 
(a) I, (b) between I and II, (c) II, (d) between II and III, (e) III, (f) between III and IV and 
(g) IV], ability to freckle, and hair colour at age 20 years (except in one case who was 
younger than 20 years at the time of study) in 27 melanoma cases and 44 controls by a 
detailed telephone questionnaire or personal interview. In an additional 11 melanoma 
cases (10 deceased, 1 demented), this data was acquired from a first degree relative; in 
one deceased case a carer provided the information; in four remaining cases (deceased/ 
change of address) no information was available. 
 
Mutation analysis 
The MC1R gene was amplified by nested PCR (13) except that 10% DMSO was 
employed in the PCR for paraffin-embedded material. Sequencing of regions previously 
reported to contain variants in Caucasians (13), including the second transmembrane 
domain (codons 64–106; sequencing primer 5′-TGATCACGTCAATGACATTGT-3′) and 
the seventh transmembrane domain (codons 278–300; sequencing primer 5′-
TGCCCAGCACACTTAAAGCGCGTGCA-3′) was carried out for melanoma cases. Controls 
were similarly sequenced through the second transmembrane domain, and screened for 
codon 294 variants by restriction fragment length polymorphism (RFLP) analysis or 
sequencing. Putative mutations were confirmed by repeat PCR from genomic DNA, and 
sequencing or RFLP analysis (codon 84, AvaII; codon 294, TaqI). Overall, optimal 
sequence was obtained in the melanoma samples in 13 cases, in the melanoma and in 
normal skin in 14 cases, in blood in seven cases and in the normal skin in nine cases. 
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